Proteome Profiler Human Phospho-Kinase Array Kit ARY003B: R&D Systems
Kit Summary

A membrane-based antibody array for the parallel determination of the relative levels of human protein kinase phosphorylation. Validated for analyte detection in cell lysates.

Key Benefits

  • Detects phosphorylation of 43 human kinases and total amounts of 2 related proteins simultaneously
  • Requires no specialized equipment
 

 

Principle of the Assay

The Proteome Profiler Human Phospho-Kinase Array Kit is a membrane-based sandwich immunoassay. Capture antibodies spotted in duplicate on nitrocellulose membranes bind to specific target proteins present in the sample (Step 1). Phosphorylation of captured proteins is detected with biotinylated phospho-specific detection antibodies (Step 2) and then visualized using chemiluminescent detection reagents (Step 3). The signal produced is proportional to the amount phosphorylation in the bound analyte.

Why Use an Antibody Array to Detect Receptor Phosphorylation?

Determining the phosphorylation of multiple kinases in a single sample can be expensive, time consuming and can require specialized equipment. Performing multiple immunoprecipitations and Western blots requires time, labor, and reagents. The use of a multiplex antibody array to detect multiple phosphorylations in a single sample can be cost-effective and also save time and sample.

 

 

Kit Contents

Each Human Phospho-Kinase Antibody Array Kit contains most of the necessary components for a ready-to-run assay without the need for specialized equipment.

  • 8 Array Membranes (4 of membrane A and 4 of membrane B)
  • 8-Well Multi-dish
  • Lysis Buffer
  • Array Buffers
  • Wash Buffer
  • Detection Antibody Cocktail A
  • Detection Antibody Cocktail B
  • Streptavidin-HRP
  • Chemiluminescent Detection Reagents
  • Transparency Overlay Template
  • Detailed product datasheet with protocol

For a complete list of the kit contents and necessary materials, please see the Materials Provided/Other Supplies Required sections of the product datasheet.

Stability and Storage

Store the unopened kit at 2°C to 8°C. Do not use past kit expiration date.

 
Simultaneously detect the relative phosphorylation of these proteins in a single sample.
Akt 1/2/3 (S473) Hck (Y411) PRAS40 (T246)
Akt 1/2/3 (T308) HSP27 (S78/S82) Pyk2 (Y402)
AMPK alpha1 (T183) HSP60 RSK1/2/3 (S380)
AMPK alpha2 (T172) JNK 1/2/3 (T183/Y185, T221/Y223) Src (Y419)
beta-Catenin Lck (Y394) STAT2 (Y689)
Chk-2 (T68) Lyn (Y397) STAT3 (S727)
c-Jun (S63) MSK1/2 (S376/S360) STAT3 (Y705)
CREB (S133) p27 (T198) STAT5a (Y699)
EGF R (Y1086) p38 alpha (T180/Y182) STAT5a/b (Y699)
eNOS (S1177) p53 (S15) STAT5b (Y699)
ERK1/2 (T202/Y204, T185/Y187) p53 (S392) STAT6 (Y641)
FAK (Y397) p53 (S46) TOR (S2448)
Fgr (Y412) p70 S6 Kinase (T421/S424) WNK-1 (T60)
Fyn (Y420) PDGF R beta (Y751) Yes (Y426)
GSK-3 alpha/beta (S21/S9) PLC gamma-1 (Y783)  

 

Assays for analytes represented in the Human Phospho-Kinase Array Kit

 

Analyte DuoSet® IC ELISA Development Systems (Total) DuoSet® IC ELISA
Development Systems (Phospho)
Surveyor™ IC or Quantikine®
ELISA Kits
Cell-based
ELISA Kits
Akt (S473)   DYC887B SUV887B  
Akt (T308)        
AMPK alpha1 (T183) DYC3197 DYC3528    
AMPK alpha2 (T172)        
beta-Catenin DYC1329   DYC1329  
Chk2 (T68)   DYC1626    
c-Jun (S63)        
CREB (S133)   DYC2510    
EGF R (Y1086) DYC1854   DEGFR0  
eNOS (S1177)        
ERK1/2 (T202/Y204, T185/Y187)   DYC1018B    
FAK (Y397) DYC4467      
Fgr (Y412)        
Fyn (Y420)        
GSK-3 alpha/beta (S21/S9) DYC2157 DYC2630   KCB1590
Hck (Y411)        
HSP27 (S78/S82) DYC1580 DYC2314   KCB2314
HSP60 DYC1800      
JNK pan (T183/Y185, T221/Y223) DYC1205 DYC1387    
Lck (Y394)        
Lyn (Y397)   DYC3936    
MSK1/2 (S376/S360)        
p27 (T198) DYC2256      
p38 alpha (T180/Y182) DYC8691B DYC869B    
p53 (S15) DYC1043 DYC1839    
p53 (S46) DYC1043 DYC1489    
p53 (S392) DYC1043 DYC2996    
p70 S6 Kinase (T389)   DYC896    
p70 S6 Kinase (T421/S424) DYC8962 DYC8965    
PDGF R beta (Y751) DYC385 DYC3096    
PLC gamma-1 (Y783)        
PRAS40 (T246)   DYC6890    
PYK2 (Y402)        
RSK1/2/3 (S380/S386/S377)   DYC889B    
Src (Y419)   DYC2685    
STAT2 (Y689)        
STAT3 (S727)        
STAT3 (Y705)   DYC4607B    
STAT5a (Y694)        
STAT5a/b (Y694/Y699)        
STAT5b (Y699)        
STAT6 (Y641)        
TOR (S2448)   DYC1665    
WNK-1(T60)   DYC4720    
Yes (Y426)   DYC3929    

Troubleshooting Guide

Data Examples
Figure 1.
View Larger Image

Figure 1. MCF-7 human breast cancer cells were either left untreated or exposed to 50 J/m2 of UV light followed by a 4 hour recovery before lysis.

Figure 2.
View Larger Image

Figure 2. A431 human epithelial carcinoma cells were either left untreated or treated with 200 ng/mL recombinant human (rh) EGF (Catalog # 236-EG) for 5 minutes.

Figure 3.
View Larger Image

Figure 3. MCF-7 human breast cancer cells were either left untreated or treated with 100 ng/mL of rhIGF-I (Catalog # 291-G1) for 1 hour.

Preparation and Storage
  • Stability & Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: Kinase Assay Kits
Protein kinases are the largest class of enzymes in the human genome. These enzymes regulate almost all cellular processes by adding phosphate groups to proteins, thereby modifying the activity, localization, and overall function of their targets. Consequently, abnormal activity of kinases underlies many diseases including cancer.
  • Alternate Names:
    Kinase Assay Kits
Related Research Areas
Citations:

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

113 Citations: Showing 1 - 10
Filter your results:

Species
Sample Type
  1. Ras-MEK Signaling Mediates a Critical Chk1-dependent DNA Damage Response in Cancer Cells
    Authors: HJ Lee, Y Cao, V Pham, E Blackwood, C Wilson, M Evangelist, C Klijn, D Stokoe, J Settleman
    Mol. Cancer Ther, 2017;0(0):. 2017
  2. Ectodomain Shedding of the Cell Adhesion Molecule Nectin-4 in Ovarian Cancer is Mediated by ADAM10 and ADAM17
    Authors: PC Buchanan, KL Boylan, B Walcheck, R Heinze, MA Geller, PA Argenta, AP Skubitz
    J. Biol. Chem, 2017;0(0):. 2017
  3. EpEX/EpCAM and Oct4 or Klf4 alone are sufficient to generate induced pluripotent stem cells through STAT3 and HIF2�
    Authors: II Kuan, KH Liang, YP Wang, TW Kuo, YJ Meir, SC Wu, SC Yang, J Lu, HC Wu
    Sci Rep, 2017;7(0):41852. 2017
  4. Induction and Differentiation of IL-10-Producing Regulatory B Cells from Healthy Blood Donors and Rheumatoid Arthritis Patients.
    Authors: Banko Z, Pozsgay J, Szili D, Toth M, Gati T, Nagy G, Rojkovich B, Sarmay G
    J Immunol, 2017;198(4):1512-1520. 2017
  5. Activation of p38 and Erk Mitogen-Activated Protein Kinases Signaling in Ocular Rosacea
    Authors: EJ Wladis, S Swamy, A Herrmann, J Yang, JA Carlson, AP Adam
    Invest. Ophthalmol. Vis. Sci, 2017;58(2):843-848. 2017
  6. Secreted Protein Acidic and Rich in Cysteine (SPARC) Enhances Cell Proliferation, Migration, and Epithelial Mesenchymal Transition, and SPARC Expression is Associated with Tumor Grade in Head and Neck Cancer.
    Authors: Chang C, Yen M, Liao S, Hsu Y, Lai C, Chang K, Hsu Y
    Int J Mol Sci, 2017;18(7):. 2017
  7. Antagonizing effects of membrane-acting androgens on the eicosanoid receptor OXER1 in prostate cancer
    Authors: K Kalyvianak, V Gebhart, N Peroulis, C Panagiotop, F Kiagiadaki, I Pediaditak, M Aivaliotis, E Moustou, M Tzardi, G Notas, E Castanas, M Kampa
    Sci Rep, 2017;7(0):44418. 2017
  8. Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene
    Authors: SA Nadeau, W An, BC Mohapatra, I Mushtaq, TA Bielecki, H Luan, N Zutshi, G Ahmad, MD Storck, M Sanada, S Ogawa, V Band, H Band
    J. Biol. Chem, 2017;292(9):3666-3682. 2017
  9. Metabolism regulates cellular functions of bone marrow-derived cells used for cardiac therapy
    Stem Cells, 2016;0(0):. 2016
  10. New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes
    Sci Rep, 2016;6(0):33165. 2016
  11. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer
    Oncotarget, 2016;0(0):. 2016
  12. Murine Polyomavirus Cell Surface Receptors Activate Distinct Signaling Pathways Required for Infection
    MBio, 2016;7(6):. 2016
  13. Characterization of non-olfactory GPCRs in human sperm with a focus on GPR18
    Sci Rep, 2016;6(0):32255. 2016
  14. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance
    Acta Pharmacol. Sin., 2016;0(0):. 2016
  15. Potential Function of Exogenous Vimentin on the Activation of Wnt Signaling Pathway in Cancer Cells
    J Cancer, 2016;7(13):1824-1832. 2016
  16. Necrotic cells influence migration and invasion of glioblastoma via NF-?B/AP-1-mediated IL-8 regulation
    Authors: SH Ahn, H Park, YH Ahn, S Kim, MS Cho, JL Kang, YH Choi
    Sci Rep, 2016;6(0):24552. 2016
  17. Phosphorylation of calcium/calmodulin-stimulated protein kinase II at T286 enhances invasion and migration of human breast cancer cells
    Sci Rep, 2016;6(0):33132. 2016
  18. Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models
    Oncotarget, 2016;7(26):40531-40545. 2016
  19. BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine
    Authors: Yuexi Gu
    Sci Rep, 2016;6(0):28217. 2016
  20. Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions.
    Authors: Purushothaman A, Bandari S, Liu J, Mobley J, Brown E, Sanderson R
    J Biol Chem, 2016;291(4):1652-63. 2016
  21. Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells.
    Authors: Skolekova S, Matuskova M, Bohac M, Toro L, Demkova L, Gursky J, Kucerova L
    Cell Commun Signal, 2016;14(1):4. 2016
  22. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells
    Oncogene, 2016;0(0):. 2016
  23. Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism
    Proc Natl Acad Sci USA, 2016;0(0):. 2016
  24. Hyperthermia Sensitizes Glioma Stem-like Cells to Radiation by Inhibiting AKT Signaling.
    Authors: Man J, Shoemake J, Ma T, Rizzo A, Godley A, Wu Q, Mohammadi A, Bao S, Rich J, Yu J
    Cancer Res, 2015;75(8):1760-9. 2015
  25. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway.
    Authors: Chang B, Johnson K, LaTocha D, Rowley J, Bryant J, Burke R, Smith R, Loriaux M, Muschen M, Mullighan C, Druker B, Tyner J
    J Hematol Oncol, 2015;8(0):39. 2015
  26. The Thrombin-Derived Host Defense Peptide GKY25 Inhibits Endotoxin-Induced Responses through Interactions with Lipopolysaccharide and Macrophages/Monocytes.
    Authors: Hansen F, Kalle-Brune M, van der Plas M, Stromdahl A, Malmsten M, Morgelin M, Schmidtchen A
    J Immunol, 2015;194(11):5397-406. 2015
  27. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells.
    Authors: Singh A, Ruan Y, Tippett T, Narendran A
    J Exp Clin Cancer Res, 2015;34(0):104. 2015
  28. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.
    Authors: Bajpe, P K, Prahallad, A, Horlings, H, Nagtegaal, I, Beijersbergen, R, Bernards, R
    Oncogene, 2015;34(4):531-6. 2015
  29. Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
    Authors: Yamada T, Amann J, Fukuda K, Takeuchi S, Fujita N, Uehara H, Iwakiri S, Itoi K, Shilo K, Yano S, Carbone D
    Cancer Res, 2015;75(19):4188-97. 2015
  30. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.
    Authors: Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W, Kim Y, Adam J, Lichter P, Solary E, Berchem G, Moussay E
    Blood, 2015;126(9):1106-17. 2015
  31. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation.
    Authors: Zhao D, Besser A, Wander S, Sun J, Zhou W, Wang B, Ince T, Durante M, Guo W, Mills G, Theodorescu D, Slingerland J
    Oncogene, 2015;34(43):5447-59. 2015
  32. Application of a Persistent Heparin Treatment Inhibits the Malignant Potential of Oral Squamous Carcinoma Cells Induced by Tumor Cell-Derived Exosomes.
    Authors: Sento S, Sasabe E, Yamamoto T
    PLoS ONE, 2015;11(2):e0148454. 2015
  33. A Peptide Mimetic of 5-Acetylneuraminic Acid-Galactose Binds with High Avidity to Siglecs and NKG2D.
    Authors: Eggink L, Spyroulias G, Jones N, Hanson C, Hoober J
    PLoS ONE, 2015;10(6):e0130532. 2015
  34. Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI.
    Authors: Laukkanen, Mikko O, Cammarota, Francesc, Esposito, Tiziana, Salvatore, Marco, Castellone, Maria D
    PLoS ONE, 2015;10(3):e0121441. 2015
  35. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
    Authors: Atefi M, Titz B, Avramis E, Ng C, Wong D, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber T, Ribas A
    Mol Cancer, 2015;14(0):27. 2015
  36. Specific activation of insulin-like growth factor-1 receptor by ginsenoside Rg5promotes angiogenesis and vasorelaxation.
    Authors: Cho Y, Hur S, Kim J, Kim J, Lee D, Choe J, Won M, Ha K, Jeoung D, Han S, Ryoo S, Lee H, Min J, Kwon Y, Kim D, Kim Y
    J Biol Chem, 2015;290(1):467-77. 2015
  37. Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation.
    Authors: Bruneau S, Neel M, Roumenina L, Frimat M, Laurent L, Fremeaux-Bacchi V, Fakhouri F
    Blood, 2015;125(6):1038-46. 2015
  38. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.
    Authors: Mailly L, Xiao F, Lupberger J, Wilson G, Aubert P, Duong F, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lutgehetmann M, Volz T, Davis C, Harris H, Mee C, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim M, Neunlist M, Zeisel M, Dandri M, McKeating J, Robinet E, Baumert T
    Nat Biotechnol, 2015;33(5):549-54. 2015
  39. Soft matrix is a natural stimulator for cellular invasiveness.
    Authors: Gu, Zhizhan, Liu, Fei, Tonkova, Elina A, Lee, Soo Youn, Tschumperlin, Daniel J, Brenner, Michael
    Mol Biol Cell, 2014;25(4):457-69. 2014
  40. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.
    Authors: Huck, Bettina, Duss, Stephan, Hausser, Angelika, Olayioye, Monilola
    J Biol Chem, 2014;289(6):3138-47. 2014
  41. Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia.
    Authors: Ray, K C, Moss, M E, Franklin, J L, Weaver, C J, Higginbotham, J, Song, Y, Revetta, F L, Blaine, S A, Bridges, L R, Guess, K E, Coffey, R J, Crawford, H C, Washington, M K, Means, A L
    Oncogene, 2014;33(7):823-31. 2014
  42. Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo.
    Authors: Naspi A, Panasiti V, Abbate F, Roberti V, Devirgiliis V, Curzio M, Borghi M, Lozupone F, Carotti S, Morini S, Gaudio E, Calvieri S, Londei P
    PLoS ONE, 2014;9(6):e98641. 2014
  43. The molecular mechanism underlying the proliferating and preconditioning effect of vitamin C on adipose-derived stem cells.
    Authors: Kim, Ji Hye, Kim, Wang-Kyu, Sung, Young Kw, Kwack, Mi Hee, Song, Seung Yo, Choi, Joon-Seo, Park, Sang Gyu, Yi, TacGhee, Lee, Hyun-Joo, Kim, Dae-Duk, Seo, Hyun Min, Song, Sun U, Sung, Jong-Hyu
    Stem Cells Dev, 2014;23(12):1364-76. 2014
  44. Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer.
    Authors: Nagalingam A, Kuppusamy P, Singh S, Sharma D, Saxena N
    Cancer Res, 2014;74(9):2617-29. 2014
  45. Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML.
    Authors: Kampen, K R, Ter Elst, A, Mahmud, H, Scherpen, F J G, Diks, S H, Peppelenbosch, M P, de Haas, V, Guryev, V, de Bont, E S J M
    Leukemia, 2014;28(3):589-99. 2014
  46. Histamine contributes to tissue remodeling via periostin expression.
    Authors: Yang, Lingli, Murota, Hiroyuki, Serada, Satoshi, Fujimoto, Minoru, Kudo, Akira, Naka, Tetsuji, Katayama, Ichiro
    J Invest Dermatol, 2014;134(8):2105-13. 2014
  47. Downstream signaling and genome-wide regulatory effects of PTK7 pseudokinase and its proteolytic fragments in cancer cells.
    Authors: Golubkov V, Strongin A
    Cell Commun Signal, 2014;12(0):15. 2014
  48. Targeting cadherin-17 inactivates Ras/Raf/MEK/ERK signaling and inhibits cell proliferation in gastric cancer.
    Authors: Lin Z, Zhang C, Zhang M, Xu D, Fang Y, Zhou Z, Chen X, Qin N, Zhang X
    PLoS ONE, 2014;9(1):e85296. 2014
  49. The epidermal growth factor receptor critically regulates endometrial function during early pregnancy.
    Authors: Large M, Wetendorf M, Lanz R, Hartig S, Creighton C, Mancini M, Kovanci E, Lee K, Threadgill D, Lydon J, Jeong J, DeMayo F
    , 2014;0(0):. 2014
  50. Mycobacteria bypass mucosal NF-kB signalling to induce an epithelial anti-inflammatory IL-22 and IL-10 response.
    Authors: Lutay N, Hakansson G, Alaridah N, Hallgren O, Westergren-Thorsson G, Godaly G
    PLoS ONE, 2014;9(1):e86466. 2014
  51. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.
    Authors: Victoni T, Gleonnec F, Lanzetti M, Tenor H, Valenca S, Porto L, Lagente V, Boichot E
    PLoS ONE, 2014;9(1):e85243. 2014
  52. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation.
    Authors: Spary L, Al-Taei S, Salimu J, Cook A, Ager A, Watson H, Clayton A, Staffurth J, Mason M, Tabi Z
    J Immunol, 2014;192(7):3101-10. 2014
  53. Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner.
    Authors: Polajeva J, Bergstrom T, Edqvist P, Lundequist A, Sjosten A, Nilsson G, Smits A, Bergqvist M, Ponten F, Westermark B, Pejler G, Forsberg Nilsson K, Tchougounova E
    Mol Oncol, 2014;8(1):50-8. 2014
  54. Extracellular UDP-glucose activates P2Y14 Receptor and Induces Signal Transducer and Activator of Transcription 3 (STAT3) Tyr705 phosphorylation and binding to hyaluronan synthase 2 (HAS2) promoter, stimulating hyaluronan synthesis of keratinocytes.
    Authors: Jokela T, Karna R, Makkonen K, Laitinen J, Tammi R, Tammi M
    J Biol Chem, 2014;289(26):18569-81. 2014
  55. Elevated O-GlcNAc levels activate epigenetically repressed genes and delay mouse ESC differentiation without affecting naive to primed cell transition.
    Authors: Speakman C, Domke T, Wongpaiboonwattana W, Sanders K, Mudaliar M, van Aalten D, Barton G, Stavridis M
    Stem Cells, 2014;32(10):2605-15. 2014
  56. Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells.
    Authors: Raimondi C, Fantin A, Lampropoulou A, Denti L, Chikh A, Ruhrberg C
    J Exp Med, 2014;211(6):1167-83. 2014
  57. IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.
    Authors: Marra P, Mathew S, Grigoriadis A, Wu Y, Kyle-Cezar F, Watkins J, Rashid M, De Rinaldis E, Hessey S, Gazinska P, Hayday A, Tutt A
    Cancer Res, 2014;74(17):4908-21. 2014
  58. Concomitant induction of apoptosis and autophagy by prostate apoptosis response-4 in hypopharyngeal carcinoma cells.
    Authors: Wang L, Chen P, Hsu L, Hsu W, Liu D, Chang C, Hsu Y, Lee J
    Am J Pathol, 2014;184(2):418-30. 2014
  59. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis.
    Authors: Lee E, Fertig E, Jin K, Sukumar S, Pandey N, Popel A
    Nat Commun, 2014;5(0):4715. 2014
  60. Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis.
    Authors: Sinkevicius, Kerstin, Kriegel, Christin, Bellaria, Kelly J, Lee, Jaewon, Lau, Allison, Leeman, Kristen, Zhou, Pengchen, Beede, Alexande, Fillmore, Christin, Caswell, Deborah, Barrios, Juliana, Wong, Kwok-Kin, Sholl, Lynette, Schlaeger, Thorsten, Bronson, Roderick, Chirieac, Lucian R, Winslow, Monte M, Haigis, Marcia C, Kim, Carla F
    Proc Natl Acad Sci U S A, 2014;111(28):10299-304. 2014
  61. Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells.
    Authors: Li, Wenjuan, Liu, Joan, Jackson, Kasey, Shi, Runhua, Zhao, Yunfeng
    PLoS ONE, 2014;9(4):e94079. 2014
  62. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.
    Authors: Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J
    Cancer Res, 2014;74(9):2444-54. 2014
  63. An increase in integrin-linked kinase non-canonically confers NF- inverted question markB-mediated growth advantages to gastric cancer cells by activating ERK1/2.
    Authors: Tseng P, Chen C, Shan Y, Chang W, Liu H, Hong T, Hsieh C, Lin S, Lin C
    Cell Commun Signal, 2014;12(1):69. 2014
  64. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Authors: Iida, Mari, Brand, Toni M, Starr, Megan M, Huppert, Evan J, Luthar, Neha, Bahrar, Harsh, Coan, John P, Pearson, Hannah E, Salgia, Ravi, Wheeler, Deric L
    Mol Cancer, 2014;13(0):242. 2014
  65. Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling.
    Authors: Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, Van Den Broecke R, Limame R, Mestdagh P, Vandesompele J, Vanhove C, Maynard D, Lehuede C, Muller C, Valet P, Gespach C, Bracke M, Cocquyt V, Denys H, De Wever O
    Cancer Res, 2014;74(23):6806-19. 2014
  66. EGF potentiation of VEGF production is cell density dependent in H292 EGFR wild type NSCLC cell line.
    Authors: Ranayhossaini D, Lu J, Mabus J, Gervais A, Lingham R, Fursov N
    Int J Mol Sci, 2014;15(10):17686-704. 2014
  67. Adenosine inhibits tumor cell invasion via receptor-independent mechanisms.
    Authors: Virtanen S, Kukkonen-Macchi A, Vainio M, Elima K, Harkonen P, Jalkanen S, Yegutkin G
    Mol Cancer Res, 2014;12(12):1863-74. 2014
  68. Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein.
    Authors: Shimizu A, Nakayama H, Wang P, Konig C, Akino T, Sandlund J, Coma S, Italiano J, Mammoto A, Bielenberg D, Klagsbrun M
    J Biol Chem, 2013;288(4):2210-22. 2013
  69. Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.
    Authors: Weidenaar A, Ter Elst A, Kampen K, Meeuwsen-de Boer T, Kamps W, Schuringa J, de Bont E
    Mol Cancer Res, 2013;11(4):339-48. 2013
  70. Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
    Authors: Stegeman H, Kaanders J, Verheijen M, Peeters W, Wheeler D, Iida M, Grenman R, van der Kogel A, Span P, Bussink J
    Mol Cancer, 2013;12(1):133. 2013
  71. Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy.
    Authors: Mir, Shakeel, Schwarze, Steven R, Jin, Ling, Zhang, Jinling, Friend, Woodrow, Miriyala, Sumitra, St Clair, Daret, Craven, Rolf J
    Autophagy, 2013;9(10):1566-78. 2013
  72. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
    Authors: Drake J, Graham N, Lee J, Stoyanova T, Faltermeier C, Sud S, Titz B, Huang J, Pienta K, Graeber T, Witte O
    Proc Natl Acad Sci U S A, 2013;110(49):E4762-9. 2013
  73. Sunlight UV-induced skin cancer relies upon activation of the p38alpha signaling pathway.
    Authors: Liu K, Yu D, Cho Y, Bode A, Ma W, Yao K, Li S, Li J, Bowden G, Dong Z, Dong Z
    Cancer Res, 2013;73(7):2181-8. 2013
  74. Activation of Src, Fyn and Yes non-receptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein.
    Authors: Szalmas A, Gyongyosi E, Ferenczi A, Laszlo B, Karosi T, Csomor P, Gergely L, Veress G, Konya J
    Virol J, 2013;10(0):79. 2013
  75. The inflammatory kinase MAP4K4 promotes reactivation of Kaposi's sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells.
    Authors: Haas D, Bala K, Busche G, Weidner-Glunde M, Santag S, Kati S, Gramolelli S, Damas M, Dittrich-Breiholz O, Kracht M, Ruckert J, Varga Z, Keri G, Schulz T
    PLoS Pathog, 2013;9(11):e1003737. 2013
  76. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Authors: Davies, Kurtis D, Mahale, Sakshi, Astling, David P, Aisner, Dara L, Le, Anh T, Hinz, Trista K, Vaishnavi, Aria, Bunn, Paul A J, Heasley, Lynn E, Tan, Aik-Choo, Camidge, D Ross, Varella-Garcia, Marileil, Doebele, Robert C
    PLoS ONE, 2013;8(12):e82236. 2013
  77. CALHM1 controls the Ca(2)(+)-dependent MEK, ERK, RSK and MSK signaling cascade in neurons.
    Authors: Dreses-Werringloer U, Vingtdeux V, Zhao H, Chandakkar P, Davies P, Marambaud P
    J Cell Sci, 2013;126(0):1199-206. 2013
  78. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction.
    Authors: Lekawanvijit S, Kumfu S, Wang B, Manabe M, Nishijima F, Kelly D, Krum H, Kompa A
    PLoS ONE, 2013;8(12):e83687. 2013
  79. Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.
    BMC Cancer, 2012;12(0):431. 2012
  80. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Authors: Joshi, Avadhut, Loilome, Watchari, Siu, I-Mei, Tyler, Betty, Gallia, Gary L, Riggins, Gregory
    PLoS ONE, 2012;7(10):e44372. 2012
  81. Puerarin suppresses proliferation of endometriotic stromal cells partly via the MAPK signaling pathway induced by 17ss-estradiol-BSA.
    Authors: Cheng W, Chen L, Yang S, Han J, Zhai D, Ni J, Yu C, Cai Z
    PLoS ONE, 2012;7(9):e45529. 2012
  82. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway.
    EMBO J., 2012;31(17):3513-23. 2012
  83. Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y.
    Authors: Olszewski U, Deally A, Tacke M, Hamilton G
    Neoplasia, 2012;14(9):813-22. 2012
  84. A novel p38-MAPK signaling axis modulates neutrophil biology in head and neck cancer.
    Authors: Dumitru CA, Fechner MK, Hoffmann TK
    J. Leukoc. Biol., 2012;91(4):591-8. 2012
  85. Concomitant targeting of EGF receptor, tgf-Beta and SRC points to a novel therapeutic approach in pancreatic cancer.
    Authors: Deharvengt S, Marmarelis M, Korc M
    PLoS ONE, 2012;7(6):e39684. 2012
  86. Proteome profiling reveals potential toxicity and detoxification pathways following exposure of BEAS-2B cells to engineered nanoparticle titanium dioxide.
    Authors: Ge Y, Bruno M, Wallace K, Winnik W, Prasad RY
    Proteomics, 2011;11(12):2406-22. 2011
  87. Influence of leucine on protein metabolism, phosphokinase expression, and cell proliferation in human duodenum1,3.
    Authors: Coeffier M, Claeyssens S, Bensifi M, Lecleire S, Boukhettala N, Maurer B, Donnadieu N, Lavoinne A, Cailleux AF, Dechelotte P
    Am. J. Clin. Nutr., 2011;93(6):1255-62. 2011
  88. Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome.
    Authors: Guo T, Lee SS, Ng WH
    Cell. Mol. Life Sci., 2011;68(11):1983-2002. 2011
  89. IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis.
    Authors: Martins AS, Ordonez JL, Amaral AT, Prins F, Floris G, Debiec-Rychter M, Hogendoorn PC, de Alava E
    PLoS ONE, 2011;6(5):e19846. 2011
  90. DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma.
    Authors: Singhal G, Akhter MZ, Stern DF
    Cancer Gene Ther., 2011;18(7):520-30. 2011
  91. EphB receptors trigger Akt activation and suppress Fas receptor-induced apoptosis in malignant T lymphocytes.
    Authors: Maddigan A, Truitt L, Arsenault R
    J. Immunol., 2011;187(11):5983-94. 2011
  92. BH3 mimetics activate multiple pro-autophagic pathways.
    Authors: Malik SA, Orhon I, Morselli E, Criollo A, Shen S, Marino G, BenYounes A, Benit P, Rustin P, Maiuri MC, Kroemer G
    Oncogene, 2011;30(37):3918-29. 2011
  93. Matrix stiffness regulation of integrin-mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells.
    Authors: Shih YR, Tseng KF, Lai HY, Lin CH, Lee OK
    J. Bone Miner. Res., 2011;26(4):730-8. 2011
  94. Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling.
    Authors: Wei Q, Jiang H, Xiao Z
    Proc. Natl. Acad. Sci. U.S.A., 2011;108(17):7004-9. 2011
  95. Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.
    Authors: Li J, Cho YY, Langfald A
    Cancer Prev Res (Phila), 2011;4(8):1190-7. 2011
  96. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.
    Authors: Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ
    Am. J. Pathol., 2011;178(3):1340-9. 2011
  97. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
    Authors: Chandarlapaty, Sarat, Sawai, Ayana, Scaltriti, Maurizio, Rodrik-Outmezguine, Vanessa, Grbovic-Huezo, Olivera, Serra, Violeta, Majumder, Pradip K, Baselga, Jose, Rosen, Neal
    Cancer Cell, 2011;19(1):58-71. 2011
  98. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation.
    Authors: Vingtdeux V, Chandakkar P, Zhao H, d'Abramo C, Davies P, Marambaud P
    FASEB J., 2011;25(1):219-31. 2011
  99. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Authors: Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL
    Oncogene, 2011;30(5):561-74. 2011
  100. Coactivated platelet-derived growth factor receptor alpha and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
    Authors: Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schoffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M
    Cancer Res., 2010;70(18):7304-14. 2010
  101. Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer.
    Authors: Tomlinson DC, Knowles MA
    Am. J. Pathol., 2010;177(5):2379-86. 2010
  102. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR).
    Authors: Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villen J, Haas W, Kovacs JJ, Shukla AK, Hara MR, Hernandez M, Lachmann A, Zhao S, Lin Y, Cheng Y, Mizuno K, Ma'ayan A, Gygi SP, Lefkowitz RJ
    Proc. Natl. Acad. Sci. U.S.A., 2010;107(34):15299-304. 2010
  103. VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms.
    Authors: Roorda BD, Ter Elst A, Scherpen FJ, Meeuwsen-de Boer TG, Kamps WA, de Bont ES
    Eur. J. Cancer, 2010;46(5):974-82. 2010
  104. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.
    Authors: Fritz V, Benfodda Z, Rodier G, Henriquet C, Iborra F, Avances C, Allory Y, de la Taille A, Culine S, Blancou H, Cristol JP, Michel F, Sardet C, Fajas L
    Mol. Cancer Ther., 2010;9(0):1740-54. 2010
  105. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
    Authors: Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, Garcia-Echeverria C, Bardeesy N, Sharpless NE, Hayes ND, Kim WY, Engelman JA, Wong KK
    Cancer Cell, 2010;17(0):547-59. 2010
  106. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation.
    Authors: Zhang H, Fagan DH, Zeng X
    Oncogene, 2010;29(17):2517-27. 2010
  107. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation.
    Authors: Chen PC, Wakimoto H, Conner D, Araki T, Yuan T, Roberts A, Seidman CE, Bronson R, Neel BG, Seidman JG, Kucherlapati R
    J. Clin. Invest., 2010;120(12):4353-65. 2010
  108. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.
    Authors: Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, Davies P, Marambaud P
    J. Biol. Chem., 2010;285(12):9100-13. 2010
  109. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1.
    Authors: Smith NJ, Stoddart LA, Devine NM, Jenkins L, Milligan G
    J. Biol. Chem., 2009;284(26):17527-39. 2009
  110. A proteomic approach to the identification of molecular targets in subsequent apoptosis of HEL cells after diosgenin-induced megakaryocytic differentiation.
    Authors: Cailleteau C, Liagre B, Beneytout JL
    J. Cell. Biochem., 2009;107(4):785-96. 2009
  111. Kaposi's sarcoma-associated herpesvirus-G protein-coupled receptor-expressing endothelial cells exhibit reduced migration and stimulated chemotaxis by chemokine inverse agonists.
    Authors: Couty JP, Lupu-Meiri M, Oron Y, Gershengorn MC
    J. Pharmacol. Exp. Ther., 2009;329(3):1142-7. 2009
  112. Neutrophils support lung colonization of metastasis-initiating breast cancer cells.
    Authors: Wculek S, Malanchi I
    Nature, 0;528(7582):413-7. 0
  113. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
    Authors: Barquilla A, Lamberto I, Heynen-Genel S, Brill L, Pasquale E
    Mol Biol Cell, 0;27(17):2757-70. 0
Expand to show all 113 Citations
Average Rating: 4.4 (Based on 7 reviews)

Have you used Proteome Profiler Human Phospho-Kinase Array Kit?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Read what people are saying who have used Proteome Profiler Human Phospho-Kinase Array Kit.

Filter by Ratings
Excellent
(4)
Very Good
(2)
Average
(1)
All Ratings
Filter by Applications
All Applications
Filter by Species
All Species

Images Ratings Applications Species Reviewed By Date Details
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
Enlarge
Very Good
  Anonymous 02/13/2017
Show
Image Details
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
: Proteome Profiler Human Phospho-Kinase Array Kit [ARY003B]

Other Experimental Details

Other Experimental DetailsGreat kit and ok value for money considering the amount of data you get!
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
Enlarge
Excellent
  Anonymous 02/12/2017
Show
Image Details
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
: Proteome Profiler Human Phospho-Kinase Array Kit [ARY003B]

Other Experimental Details

Other Experimental DetailsUsed with human samples. Image shown was at 1 minute. Other 'dots' appeared at increased exposure. Kit very good overall. Good quality result and easy to use
  Excellent
  Anonymous 01/03/2017
Show

Other Experimental Details

Other Experimental DetailsThis array is an excellent tool for screening potential phospho-kinases and related targets. However, it would be nice that if the total level of non-phosphorylated proteins be visualized at the same time on the membrane. In this case, the phosphorylated signals can be normalized.
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
Enlarge
Average
  Anonymous 10/28/2016
Show
Image Details
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
: Proteome Profiler Human Phospho-Kinase Array Kit [ARY003B]

Other Experimental Details

Other Experimental DetailsAntibodies could not be sourced to validate some of the targets.
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
Enlarge
Excellent
  Anonymous 10/14/2016
Show
Image Details
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
: Proteome Profiler Human Phospho-Kinase Array Kit [ARY003B]
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
Enlarge
Excellent
  Anonymous 08/09/2016
Show
Image Details
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
: Proteome Profiler Human Phospho-Kinase Array Kit [ARY003B]
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
Enlarge
Very Good
  Anonymous 10/26/2015
Show
Image Details
 Proteome Profiler Human Phospho-Kinase Array Kit ARY003B
: Proteome Profiler Human Phospho-Kinase Array Kit [ARY003B]

Summary

Sample TestedCell Lysates

Other Experimental Details

Other Experimental DetailsThis was control and didnt show any non specific bindings.
Specificity: Specific
Sensitivity: Sensitive
Buffer: BSA
Dilution: 1:1000

FAQs

  1. Does Lysis Buffer 6 in the Proteome Profiler™ Array contain phosphatase and protease inhibitors?

    • Lysis Buffer 6 contains phosphatase inhibitors but not protease inhibitors. If desired, protease inhibitors can be added to the lysis buffer immediately prior to use. We recommend 10 μg/ml Aprotinin (Tocris; Catalog # 4139), 10 μg/ml Leupeptin (Tocris; Catalog # 1167), and 10 μg/ml Peptstatin (Tocris; Catalog # 1190).

  2. Does Lysis Buffer 6 in the Proteome Profiler™ Array contain phosphatase and protease inhibitors?

    • Lysis Buffer 6 contains phosphatase inhibitors but not protease inhibitors. If desired, protease inhibitors can be added to the lysis buffer immediately prior to use. We recommend 10 μg/ml Aprotinin (Tocris; Catalog # 4139), 10 μg/ml Leupeptin (Tocris; Catalog # 1167), and 10 μg/ml Peptstatin (Tocris; Catalog # 1190).

View all Proteome Profiler Antibody Array FAQs

Order Details

Contact Information

R&D Systems Guarantee

Feedback

Customer Information